EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA
Human medicines European public assessment report (EPAR): Trulicity, dulaglutide, Date of authorisation: 21/11/2014, Revision: 21, Status: Authorised
Submitted by Anonymous (not verified) on 30 January 2026 - 10:52
Human medicines European public assessment report (EPAR): Trulicity, dulaglutide, Date of authorisation: 21/11/2014, Revision: 21, Status: Authorised
First immunotherapy-based treatment recommended for advanced anal cancer
Submitted by Anonymous (not verified) on 30 January 2026 - 10:50
First immunotherapy-based treatment recommended for advanced anal cancer
List of centrally authorised products with safety-related changes to the product information
Submitted by Anonymous (not verified) on 30 January 2026 - 10:00
List of centrally authorised products with safety-related changes to the product information
Final programming document 2026-28
Submitted by Anonymous (not verified) on 30 January 2026 - 9:04
Final programming document 2026-28
List of industry subject matter experts and list of planned calls for industry subject matter experts
Submitted by Anonymous (not verified) on 30 January 2026 - 8:10
List of industry subject matter experts and list of planned calls for industry subject matter experts
EMEA-002109-PIP01-16
Submitted by Anonymous (not verified) on 29 January 2026 - 15:50
EMEA-002109-PIP01-16
EMEA-002828-PIP01-20
Submitted by Anonymous (not verified) on 29 January 2026 - 15:49
EMEA-002828-PIP01-20
EMEA-003393-PIP01-23
Submitted by Anonymous (not verified) on 29 January 2026 - 15:48
EMEA-003393-PIP01-23
EMEA-002572-PIP01-19
Submitted by Anonymous (not verified) on 29 January 2026 - 15:47
EMEA-002572-PIP01-19